drugset / Trial / NCT01456663

A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects

NCT01456663

Phase 1 Completed 118 enrolled Novartis Pharmaceuticals
NaParallel-groupOpen-labelOther

Summary

This study will assess the pharmacokinetics of AFQ056 in subjects with mild, moderate, severe hepatic impairment compared with healthy control subjects.

Timeline

Start
2011-05
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavoglurant Small molecule

Indications

No indication recorded.